<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894450</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0402</org_study_id>
    <nct_id>NCT02894450</nct_id>
  </id_info>
  <brief_title>Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years</brief_title>
  <acronym>AOD-SA</acronym>
  <official_title>Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay (Xaban) Higher Among Those Aged Over 75 Years, as AOD for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate whether there is a link between clinical and&#xD;
      biological variables and bioassay high xaban in elderly patients as part of an unscheduled&#xD;
      hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bioassay direct oral anticoagulants</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>bioassay xaban</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 75 years under anticoagulant treatment 'xaban' (dabigatran, rivaroxaban,&#xD;
        Apixaban) for atrial fibrillation, hospital unscheduled manner in Medicine and Geriatric&#xD;
        services Versatile Service Home Emergency CHU Nantes and where a hemostatic balance is&#xD;
        expected to be offered the study.&#xD;
&#xD;
        The recruitment will be made on a 6-month period (November 2014 - April 2015). Bioassay&#xD;
        'xaban' will be made from the remainder of the tube removed for hemostasis tests provided&#xD;
        in the usual care of patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 75 years&#xD;
&#xD;
          -  Entering SAU or MPG (Nantes University Hospital) as part of an unscheduled&#xD;
             hospitalization for acute or subacute disease (About MPG, will be included patients&#xD;
             admitted to the department within 48 hours of calling the doctor)&#xD;
&#xD;
          -  In xaban to entry (dabigatran, rivaroxaban, Apixaban) for non-valvular atrial&#xD;
             fibrillation&#xD;
&#xD;
          -  In whom hemostasis tests will be prescribed as part of usual care&#xD;
&#xD;
          -  Patient has given its verbal agreement&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients with the following criteria may not be included:&#xD;
&#xD;
          -  Patients refusing to participate in the study&#xD;
&#xD;
          -  Patients under guardianship&#xD;
&#xD;
          -  Inability to obtain the date and time of the last dose of xaban&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Chevalet, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>oral anticoagulant</keyword>
  <keyword>bioassay</keyword>
  <keyword>elderly subject</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

